Konstantin Masliantsev

Dr. Konstantin Masliantsev

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2021 in Cells
Verified
Journal Article
Open access
PDF file
KMKonstantin Masliantsev
Konstantin Masliantsev
LTLucie Karayan Tapon
Lucie Karayan Tapon
PGPierre-Olivier Guichet
Pierre-Olivier Guichet
The Hippo signaling pathway is a highly conserved pathway involved in tissue development and regeneration that controls organ size through the regulation of cell proliferation and apoptosis. The core Hippo pathway is composed of a block of kinases, MST1/2 (Mammalian STE20-like protein kinase 1/2) and LATS1/2 (Large tumor suppressor 1/2), which inhibits nuclear translocation of YAP/TAZ (Yes-Associated Protein 1/Transcriptional co-activator with PDZ-binding motif) and its downstream association with the TEAD (TEA domain) family of transcription factors. This pathway was recently shown to be involved in tumorigenesis and metastasis in several cancers such as lung, breast, or colorectal cancers but is still poorly investigated in brain tumors. Gliomas are the most common and the most lethal primary brain tumors representing about 80% of malignant central nervous system neoplasms. Despite intensive clinical protocol, the prognosis for patients remains very poor due to systematic relapse and treatment failure. Growing evidence demonstrating the role of Hippo signaling in cancer biology and the lack of efficient treatments for malignant gliomas support the idea that this pathway could represent a potential target paving the way for alternative therapeutics. Based on recent advances in the Hippo pathway deciphering, the main goal of this review is to highlight the role of this pathway in gliomas by a state-of-the-art synthesis.

28 August 2018 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
PGPierre-Olivier Guichet
Pierre-Olivier Guichet
KMKonstantin Masliantsev
Konstantin Masliantsev
GTGaëlle Tachon
Gaëlle Tachon
CPChristos Petropoulos
Christos Petropoulos
JGJulie Godet
Julie Godet
LTLucie Karayan Tapon
Lucie Karayan Tapon

Verified
Journal Article
Open access
PDF file
GTGaelle Tachon
Gaelle Tachon
UCUlrich Cortes
Ulrich Cortes
PGPierre-Olivier Guichet
Pierre-Olivier Guichet
PRPierre Rivet
Pierre Rivet
ABAnais Balbous
Anais Balbous
LKLucie Karayan-Tapon
Lucie Karayan-Tapon
“Glioma Stem Cells” (GSCs) are known to play a role in glioblastoma (GBM) recurrence. Homologous recombination (HR) defects and cell cycle checkpoint abnormalities can contribute concurrently to the radioresistance of GSCs. DNA repair protein RAD51 homolog 1 (RAD51) is a crucial protein for HR and its inhibition has been shown to sensitize GSCs to irradiation. The aim of this study was to examine the consequences of ionizing radiation (IR) for cell cycle progression in GSCs. In addition, we intended to assess the potential effect of RAD51 inhibition on cell cycle progression. Five radiosensitive GSC lines and five GSC lines that were previously characterized as radioresistant were exposed to 4Gy IR, and cell cycle analysis was done by fluorescence-activated cell sorting (FACS) at 24, 48, 72, and 96 h with or without RAD51 inhibitor. Following 4Gy IR, all GSC lines presented a significant increase in G2 phase at 24 h, which was maintained over 72 h. In the presence of RAD51 inhibitor, radioresistant GSCs showed delayed G2 arrest post-irradiation for up to 48 h. This study demonstrates that all GSCs can promote G2 arrest in response to radiation-induced DNA damage. However, following RAD51 inhibition, the cell cycle checkpoint response differed. This study contributes to the characterization of the radioresistance mechanisms of GSCs, thereby supporting the rationale of targeting RAD51-dependent repair pathways in view of radiosensitizing GSCs.

1 June 2019 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
GTGaelle Tachon
Gaelle Tachon
KMKonstantin Masliantsev
Konstantin Masliantsev
PRPierre Rivet
Pierre Rivet
CPChristos Petropoulos
Christos Petropoulos
JGJulie Godet
Julie Godet
LTLucie Karayan Tapon
Lucie Karayan Tapon

16 December 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
KMKonstantin Masliantsev
Konstantin Masliantsev
BPBaptiste Pinel
Baptiste Pinel
ABAnaïs Balbous
Anaïs Balbous
PGPierre-Olivier Guichet
Pierre-Olivier Guichet
GTGaëlle Tachon
Gaëlle Tachon
LTLucie Karayan Tapon
Lucie Karayan Tapon
Impact of STAT3 phosphorylation in glioblastoma stem cells radiosensitization and patient outcome Impact of STAT3 phosphorylation in glioblastoma stem cells radiosensitization and patient outcome

25 November 2021 in Cancers
Verified
Journal Article
Open access
PDF file
GTGaelle Tachon
Gaelle Tachon
KMKonstantin Masliantsev
Konstantin Masliantsev
PRPierre Rivet
Pierre Rivet
ACamandine chepied
amandine chepied
SMSerge Milin
Serge Milin
PGPierre-Olivier Guichet
Pierre-Olivier Guichet
The high expression of MEOX2 transcription factor is closely associated with poor overall survival in glioma. MEOX2 has recently been described as an interesting prognostic biomarker, especially for lower grade glioma. MEOX2 has never been studied in glioma stem-like cells (GSC), responsible for glioma recurrence. The aim of our study was to investigate the role of MEOX2 in GSC. Loss of function approach using siRNA was used to assess the impact of MEOX2 on GSC viability and stemness phenotype. MEOX2 was localized in the nucleus and its expression was heterogeneous between GSCs. MEOX2 expression depends on the methylation state of its promoter and is strongly associated with IDH mutations. MEOX2 is involved in cell proliferation and viability regulation through ERK/MAPK and PI3K/AKT pathways. MEOX2 loss of function correlated with GSC differentiation and acquisition of neuronal lineage characteristics. Besides, inhibition of MEOX2 is correlated with increased expression of CDH10 and decreased pFAK. In this study, we unraveled, for the first time, MEOX2 contribution to cell viability and proliferation through AKT/ERK pathway and its potential involvement in phenotype and adhesion properties of GSC.